Janus kinase inhibitors in dermatology: A systematic review.
메타분석
4/5 보강
TL;DR
A systematic review of PubMed and ClinicalTrials.gov shows that while JAK inhibitors hold promise for many skin disorders, there are still gaps regarding the correct dosing and safety profile of these medications for dermatologic indications.
📑 코퍼스 인용 관계
· 인용됨 7
📑 인용한 논문 (6) ▾
- Disparities in Janus kinase inhibitor access for alopecia areata: a retrospective analysis… International journal of women's dermatology · 2024
- Acne exacerbation after tofacitinib treatment for alopecia areata. Dermatology reports · 2022
- [Janus kinase inhibitors for the treatment of alopecia areata]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2022
- Effective use of oral tofacitinib and phototherapy in a patient with concomitant alopecia … Clinical case reports · 2020
- Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia area… JAAD case reports · 2019
- Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitili… Dermatology and therapy · 2019
연도별 인용 (2017–2026) · 합계 141
OpenAlex 토픽 ·
Psoriasis: Treatment and Pathogenesis
Cytokine Signaling Pathways and Interactions
Dermatology and Skin Diseases
A systematic review of PubMed and ClinicalTrials.gov shows that while JAK inhibitors hold promise for many skin disorders, there are still gaps regarding the correct dosing and safety profile of these
- 연구 설계 systematic review
APA
Rony Shreberk‐Hassidim, Yuval Ramot, Abraham Zlotogorski (2017). Janus kinase inhibitors in dermatology: A systematic review.. Journal of the American Academy of Dermatology, 76(4), 745-753.e19. https://doi.org/10.1016/j.jaad.2016.12.004
MLA
Rony Shreberk‐Hassidim, et al.. "Janus kinase inhibitors in dermatology: A systematic review.." Journal of the American Academy of Dermatology, vol. 76, no. 4, 2017, pp. 745-753.e19.
PMID
28169015 ↗
Abstract 한글 요약
[BACKGROUND] Janus kinase (JAK) inhibitors are emerging as a promising new treatment modality for many inflammatory conditions.
[OBJECTIVE] Our aim was to systematically review the available data on the use of JAK inhibitors in cutaneous diseases.
[METHODS] This is a systematic review of PubMed and ClinicalTrials.gov.
[RESULTS] One hundred thirty-four articles matched our search terms, of which 78 were original articles and 12 reports on adverse events. Eighteen clinical trials were found. JAK inhibitors have been extensively studied for psoriasis, showing beneficial results that were comparable to the effects achieved by etanercept. Favorable results were also observed for alopecia areata. Promising preliminary results were reported for vitiligo, dermatitis, graft versus host disease, cutaneous T cell lymphoma, and lupus erythematosus. The most common adverse events reported were infections, mostly nasopharyngitis and upper respiratory tract infections.
[LIMITATIONS] It was not possible to perform a meta-analysis of the results.
[CONCLUSIONS] This systematic review shows that while JAK inhibitors hold promise for many skin disorders, there are still gaps regarding the correct dosing and safety profile of these medications for dermatologic indications. Additional trials are necessary to address these gaps.
[OBJECTIVE] Our aim was to systematically review the available data on the use of JAK inhibitors in cutaneous diseases.
[METHODS] This is a systematic review of PubMed and ClinicalTrials.gov.
[RESULTS] One hundred thirty-four articles matched our search terms, of which 78 were original articles and 12 reports on adverse events. Eighteen clinical trials were found. JAK inhibitors have been extensively studied for psoriasis, showing beneficial results that were comparable to the effects achieved by etanercept. Favorable results were also observed for alopecia areata. Promising preliminary results were reported for vitiligo, dermatitis, graft versus host disease, cutaneous T cell lymphoma, and lupus erythematosus. The most common adverse events reported were infections, mostly nasopharyngitis and upper respiratory tract infections.
[LIMITATIONS] It was not possible to perform a meta-analysis of the results.
[CONCLUSIONS] This systematic review shows that while JAK inhibitors hold promise for many skin disorders, there are still gaps regarding the correct dosing and safety profile of these medications for dermatologic indications. Additional trials are necessary to address these gaps.
추출된 의학 개체 (NER)
상태/진단
원형 탈모증 alopecia areata
전체 NER 표 보기
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 질환 | alopecia areata
|
원형 탈모증 | dict | 1 |
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Alopecia Areata
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Azetidines
- Dermatologic Agents
- Drug Eruptions
- Humans
- Janus Kinases
- Molecular Targeted Therapy
- Nitriles
- Piperidines
- Protein Kinase Inhibitors
- Psoriasis
- Purines
- Pyrazoles
- Pyrimidines
- Pyrroles
- Randomized Controlled Trials as Topic
- Signal Transduction
- Skin Diseases
- Sulfonamides
- JAK inhibitors
- alopecia areata
- atopic dermatitis
… 외 7개
인용 관계
그래프 OA 노드: 6/7 (86%)
· 참조 0편 · 후속 6편
이 논문을 인용한 후속 연구 7
- Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Al…
- Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata.
- Epigallocatechin-3 Gallate Inhibits and Reduces CD8 MKG2D Lymphocytes of Alopecia Areata Patients.
- [Janus kinase inhibitors for the treatment of alopecia areata].
- Disparities in Janus kinase inhibitor access for alopecia areata: a retrospective analysis.
- Acne exacerbation after tofacitinib treatment for alopecia areata.
- Effective use of oral tofacitinib and phototherapy in a patient with concomitant alopecia areata, vi…
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
📖 비슷한 OA 논문 — 같은 카테고리, 무료 전문 가능
-
Alopecia areata.
TL;DRAlopecia areata is difficult to manage medically, but recent advances in understanding the molecular mechanisms have revealed new treatments and the possibility of remission in the…
-
Epidemiology and burden of alopecia areata: a systematic review.
TL;DRAA is the most prevalent autoimmune disorder and the second most prevalent hair loss disorder after androgenetic alopecia, and the lifetime risk in the global population is approxi…
-
Two Phase 3 Trials of Baricitinib for Alopecia Areata.
TL;DRIn two phase 3 trials involving patients with severe alopecia areata, oral baricitinib was superior to placebo with respect to hair regrowth at 36 weeks.
-
Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics.
TL;DRAlthough a variety of medical, surgical, light‐based and nutraceutical treatment options are available to slow or reverse the progression of AGA, it can be challenging to select ap…
-
Alopecia areata: A multifactorial autoimmune condition.
TL;DRVarious genetic and environmental factors that cause autoimmunity are discussed and the immune mechanisms that lead to hair loss in alopecia areata patients are described.